Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MB BCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MBBCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Transcript
There are several potential biomarkers that have emerged in recent years, but in what areas and for what treatments are biomarkers still urgently needed to guide treatment decisions?
I think there are tumor types that are rarer, in which biomarker testing is still in its infancy. So, for those tumor types, I think there is still a way to go. Also, there are tumor types that appear to respond better to combinations, and we’re in an era of giving combinations, either with other immunotherapy agents or with chemotherapy.
So, I think biomarker testing is going to evolve to not just look at checkpoint inhibitor monotherapy, but also to look at combinations. And the biomarkers may be different depending on what treatment we give.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More